XLXiaoyang Lu

Xiaoyang Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaoyang Lu has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Dongsheng Hong

    Department of Clinical Pharmacy, Zhejiang Provincial Engineering Center for Innovative Drug Clinical Research and Application, Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China

    7 shared publications
  • Na Chen

    Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

    6 shared publications
  • Saiping Jiang

    Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    6 shared publications
  • Lin Liu

    Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China

    5 shared publications
  • Lu Li

    Department of Clinical Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

    5 shared publications
  • Rongrong Wang

    Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    5 shared publications

Latest Publications

  • Open Access

    Acute kidney injury of intravenous colistin sulfate compared with colistimethate sodium: a real-world, retrospective cohort study

    by Ping Yang, Wuping Shuai, Yuanzhi Ju, Hongping Zhu, Rongrong Wang, Xiaoyang Lu, Saiping Jiang

    The nephrotoxicity associated with polymyxins is a critical safety concern in clinical practice. The aim of this study was to compare the nephrotoxicity of patients treated with colistin sulfate (CS) and colistin methanesulfonate (CMS). Data on inpatients who received intravenous colistin (CS) or colistin methanesulfonate (CMS) for over 72 h were collected from January to December 2023. The primary outcome was the incidence of acute kidney injury (AKI) associated with polymyxins, while the secondary outcome was 30-day all-cause mortality. Furthermore, Cox proportional hazard regression analysis was used to identify the risk factors of polymyxin-induced AKI. A total of 291 patients were included in this study. The overall incidence of AKI was significantly higher in patients who received CMS compared to those who received CS in the unmatched cohort (29.70% vs. 7.37%) and in the propensity score matching (PSM) cohort (26.30% vs. 10.00%), respectively. However, 30-day all-cause mortality was significantly higher in the CS cohort than in the CMS cohort before (27.37% vs. 15.84%) and after (33.75% vs. 15.00%) PSM. CMS therapy and a lower baseline estimated glomerular filtration rate (eGFR) were identified as independent risk factors for polymyxin-induced AKI. This was the first study to investigate the nephrotoxicity difference between CS and CMS to our best knowledge. In this study, the incidence rate of AKI was significantly lower in the CS cohort compared with the CMS cohort, however, 30-day all-cause mortality rate was significantly higher in the CS cohort than in the CMS cohort. Further validation of these findings requires more prospective multicentre studies with a large sample size.


  • Open Access

    Trends in Antihypertensive Drug Use and Irrational Prescriptions Among Elderly Patients in China (2016–2023): A Nationwide Multi-Center Cross-Sectional Survey Study

    by Dongsheng Hong, Weihao Chen, Shuangshuang Du, Jinshuai Ren, Duo Lv, Wenya Shan, Xiaoyang Lu, Qingwei Zhao

    Purpose: Hypertension is a common chronic condition among the elderly, and the rational use of antihypertensive medications is critical for blood pressure control. This study aimed to investigate trends in the use and irrational prescription of antihypertensive medications among elderly patients with hypertension in China from 2016 to 2023. Patients and Methods: A retrospective cross-sectional design was applied to analyze the prescription of antihypertensive drugs in hypertensive patients aged 65 years and above, utilizing outpatient electronic medical record data from 78 hospitals in nine cities in China from 2016 to 2023. Antihypertensive medications were categorized into nine classes based on hypertension treatment guidelines. Annual trends in the use of these medications were analyzed using Annual Percentage Change (APC). Irrational prescriptions were defined as contraindicated medication prescriptions and inappropriate combination medication. Poisson regression models were employed to analyze trends and influencing factors for irrational prescriptions. Results: The number of patients increased from 396,408 to 542,215 during the study period. Calcium Channel Blockers had the highest usage but showed a slight decrease (APC=− 3.46%, P=0.011), while β-blockers showed a slight increase (APC=1.48%, P=0.028). The overall proportion of first-line antihypertensive prescriptions was 97.47% but showed a slight declining trend (APC=− 0.66%, P=0.004). The rates of inappropriate combination medication and overall irrational prescriptions decreased, while the rate of contraindicated medication prescriptions increased (P< 0.001). Factors including male gender, advanced age (≥ 85 years), northern regions, primary healthcare settings, and geriatrics departments were associated with higher risks of contraindicated medications. Conclusion: This study reveals the trends and patterns in antihypertensive medication use among elderly hypertensive patients in China from 2016 to 2023. While the overall use of first-line antihypertensive drugs remained high, there were differences across subgroups. The increasing rate of contraindicated medications and the identification of high-risk groups and clinical settings provide important insights for optimizing antihypertensive treatment in elderly populations.


  • Open Access

    A multicenter clinical study on the incidence and influencing factors of cephalosporin-induced anaphylaxis

    by Ping Yang, Dandan Dai, Qingyu Li, Haichao Zhan, Xumei Li, Min He, Na Chen, Saiping Jiang, Xiaoyang Lu

    Objective To investigate the incidence and influencing factors of allergic reactions to cephalosporins. Methods A cross-sectional study of 29 medical institutions in Zhejiang Province was conducted from April 2021 to June 2021. The incidence of allergic reactions to cephalosporins was investigated, and the influencing factors of cephalosporin-induced allergic reactions were analyzed by Poisson regression. Results A total of 56 155 patients were included in this study. The total incidence of allergic reactions to cephalosporin was 1.67‰, the highest incidence of anaphylaxis occurred for ceftizoxime (4.27‰), followed by ceftriaxone (3.49‰) and cefotaxime (2.40‰). There was no significant difference in the incidence of allergic reactions between patients with negative skin tests and those without skin tests (1.75‰ vs. 1.63‰, RR=1.07, 95%CI: 0.70-1.63, P>0.05). Poisson regression showed that body mass index (BMI) 2 (RR=2.43, 95%CI: 1.23-4.82, P<0.05) and history of β-lactam antibiotics allergy (RR=33.88, 95%CI: 1.47-781.12, P<0.05) increased cephalosporin-induced anaphylaxis. Compared with cefuroxime, the risk of allergic reactions was increased for ceftriaxone (RR=3.08, 95%CI: 1.70-5.59, P<0.01), ceftazidime (RR=1.89, 95%CI: 1.03-3.47, P<0.05), and ceftizoxime (RR=3.74, 95%CI: 1.64-8.50, P<0.01). Conclusions Lower BMI and history of β-lactam antibiotics allergy increase the risk of cephalosporin allergic reactions. The routine skin test may not reduce the occurrence of allergic reactions to cephalosporins.


  • Open Access

    Population Pharmacokinetics of Isavuconazole in Adult: A Systematic Review

    by Na Chen, Xiaojuan Wang, Yinyan Li, Ping Yang, Mingzhu Huang, Xiaoyang Lu

    Isavuconazole (ISA) is a second generation broad-spectrum triazole antifungal drug derived from voriconazole structure, and its oral capsules is currently the only oral preparation approved for invasive mucormycosis. In recent years, population pharmacokinetic studies of ISA have been reported continuously. This paper aims to summarize the characteristics of population pharmacokinetic models of ISA in adults, and provide theoretical basis for individualized administration of ISA. We systematically searched PubMed, Embase, CNKI, Wanfang, VIP and other databases to collect population pharmacokinetic models published from the establishment of the database to March 2023. A total of 6 studies were included in this review, including healthy men and women, invasive fungal infections with malignant tumors or neutropenia, solid organ transplantation. The dose of ISA was 40– 400mg for single-dose. The multiple-dose of ISA was 200mg every 8 hours for the first 48 hours and then 200mg once daily. All studies used a two-compartment model, first-order elimination. For oral formulations, except for one study that used first-order absorption, the others used Weibull absorption. Body mass index (BMI) was the most common covariable, followed by total body weight, lean body mass, race, sex, population type (healthy volunteers/patients), and creatinine clearance. These studies included several covariates, and the clearance rate (CL) was similar among populations. In the future, external validation and population pharmacokinetic studies in special populations such as patients with severe liver disease and ECMO support are needed.


  • Open Access

    The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis

    by Dongsheng Hong, Duo Lv, Jiaying Wu, Xin Li, Qingwei Zhao, Xiaoyang Lu, Lu Li

    Background: DIP is a new medical insurance payment system developed in China which was implemented in Guangzhou in January 2018, but few studies have focused on its intervention effect on the drug burden of elderly hypertensive patients. Methods: Nine medical institutions in Guangzhou, China, were selected, among which, daily full medical orders of elderly hypertensive inpatients from 2016 to 2020 were randomly collected. To assess the impact of DIP policy intervention on patient drug burden, we took the data after policy implementation in January 2018, as the intervention data, and applied a segmented regression model with interrupted time series to analyze the trend and changes in average daily drug costs per month and medication structure, stratified by age, sex, and inpatient department. Results: A total of 34,276 elderly hypertensive patients’ daily full medical orders were obtained. The immediate level change of drug costs after intervention was − 23.884 RMB/month (P = 0.652), and the trend change was statistically significant (− 15.642 RMB/month, P = 0.002). The relative cumulative effect at the end of the study was − 78.860% (95% CI: − 86.087% to − 69.076%), and the intervention effect was more significant in surgical and male patients. The analysis of drug structure changes showed that after the implementation of the DIP policy intervention, the proportion of anti-infective drugs, anti-tumor drugs, and biological products all showed a significant downward trend (P < 0.05), while nutritional drugs showed a significant upward trend (P = 0.011), but no immediate horizontal change in slope was observed. Conclusion: The typical practice in China showed that DIP policy intervention can improve the drug burden of elderly hypertensive hospitalized patients and has a stable long-term effect, and the intervention effect is not consistent across different clinical department and populations with different characteristics, and it would also cause changes in the medication structure.


  • Open Access

    Recent advances of cell membrane-coated nanoparticles for therapy of bacterial infection

    by Yue Song, Xia Zheng, Juan Hu, Subo Ma, Kun Li, Junyao Chen, Xiaoling Xu, Xiaoyang Lu, Xiaojuan Wang

    The rapid evolution of antibiotic resistance and the complicated bacterial infection microenvironments are serious obstacles to traditional antibiotic therapy. Developing novel antibacterial agents or strategy to prevent the occurrence of antibiotic resistance and enhance antibacterial efficiency is of the utmost importance. Cell membrane-coated nanoparticles (CM-NPs) combine the characteristics of the naturally occurring membranes with those of the synthetic core materials. CM-NPs have shown considerable promise in neutralizing toxins, evading clearance by the immune system, targeting specific bacteria, delivering antibiotics, achieving responsive antibiotic released to the microenvironments, and eradicating biofilms. Additionally, CM-NPs can be utilized in conjunction with photodynamic, sonodynamic, and photothermal therapies. In this review, the process for preparing CM-NPs is briefly described. We focus on the functions and the recent advances in applications of several types of CM-NPs in bacterial infection, including CM-NPs derived from red blood cells, white blood cells, platelet, bacteria. CM-NPs derived from other cells, such as dendritic cells, genetically engineered cells, gastric epithelial cells and plant-derived extracellular vesicles are introduced as well. Finally, we place a novel perspective on CM-NPs’ applications in bacterial infection, and list the challenges encountered in this field from the preparation and application standpoint. We believe that advances in this technology will reduce threats posed by bacteria resistance and save lives from infectious diseases in the future.


  • Open Access

    TPGS-based and S-thanatin functionalized nanorods for overcoming drug resistance in Klebsiella pneumonia

    by Xiaojuan Wang, Xiaoling Xu, Shaojun Zhang, Na Chen, Yunfeng Sun, Kuifen Ma, Dongsheng Hong, Lu Li, Yongzhong Du, Xiaoyang Lu, et al.

    Tigecycline is regarded as the last line of defense to combat multidrug-resistant Klebsiella pneumoniae. However, increasing utilization has led to rising drug resistance and treatment failure. Here, we design a D-alpha tocopheryl polyethylene glycol succinate-modified and S-thanatin peptide-functionalized nanorods based on calcium phosphate nanoparticles for tigecycline delivery and pneumonia therapy caused by tigecycline-resistant Klebsiella pneumoniae. After incubation with bacteria, the fabricated nanorods can enhance tigecycline accumulation in bacteria via the inhibitory effect on efflux pumps exerted by D-alpha tocopheryl polyethylene glycol succinate and the targeting capacity of S-thanatin to bacteria. The synergistic antibacterial capacity between S-thanatin and tigecycline further enhances the antibacterial activity of nanorods, thus overcoming the tigecycline resistance of Klebsiella pneumoniae. After intravenous injection, nanorods significantly reduces the counts of white blood cells and neutrophils, decreases bacterial colonies, and ameliorates neutrophil infiltration events, thereby largely increasing the survival rate of mice with pneumonia. These findings may provide a therapeutic strategy for infections caused by drug-resistant bacteria.


  • Open Access

    Mitofusin2 Promotes β Cell Maturation from Mouse Embryonic Stem Cells via Sirt3/Idh2 Activation

    by Li Lu, Li Zhitao, Cui Nannan, Huang Mingzhu, Hu Xiaoping, Hong Dongsheng, Pan Zongfu, Lu Xiaoyang

    β cell dysfunction is the leading cause of diabetes. Adult β cells have matured glucose-stimulated insulin secretion (GSIS), whereas fetal and neonatal β cells are insensitive to glucose and are functionally immature. However, how β cells mature and acquire robust GSIS is not fully understood. Here, we explored the potential regulatory proteins of β cell maturation process and the capacity for GSIS. Combined with the data from public databases, we found that the gene expression of Mitofusin2 (Mfn2) showed an increasing trend from mouse neonatal β cells to mature β cells. Moreover, its protein expression increased during mouse embryonic pancreas development and β cell differentiation from mouse embryonic stem cells. Knocking down Mfn2 reduced Urocortin3 (Ucn3) expression, GSIS, and ATP production in induced β cells, while overexpressing it had the opposite effect. However, neither Mfn2 knockdown nor overexpression affected the differentiation rate of insulin-positive cells. In immature and mature β cells, Mfn2 and its correlated genes were enriched in tricarboxylic acid (TCA) cycle-related pathways. The expressions of Sirtuin 3 (Sirt3) and isocitrate dehydrogenase 2 (NADP+) and mitochondrial (Idh2) were Mfn2-regulated during β cell differentiation. Inhibiting Idh2 or Sirt3 reduced cellular ATP content and insulin secretion levels that increased by Mfn2 overexpression. Thus, Mfn2 modulated the induced β cell GSIS by influencing the TCA cycle through Sirt3/Idh2 activation. We demonstrated that Mfn2 promoted embryonic stem cell-derived β cell maturation via the Sirt3/Idh2 pathway, providing new insights into β cell development. Our data contribute to understanding diabetes pathogenesis and offer potential new targets for β cell regeneration therapies.


  • Open Access

    Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese Acute Myeloid Leukemia Patients by a Validated UPLC-MS/MS Method

    by Xi Yang, Chen Mei, Xiaoying He, Lingjuan He, Xiaoyang Lu, Hongyan Tong, Yan Lou

    Venetoclax has emerged as a breakthrough for treatment of leukemia with a wide interindividual variability in pharmacokinetics. Herein, a rapid, sensitive, and reliable UPLC-MS/MS method for quantification of venetoclax in plasma was developed and validated. The method was operated in the multiple-reaction monitoring (MRM) mode to detect venetoclax at m/z transition 868.5 > 321.0 and IS at 875.5 > 321.0, respectively. Protein precipitation prior to injection into the LC-MS/MS and the analyte was separated on an ACQUITY UPLC BEH C18 column by gradient elution with acetonitrile and 0.1% formic acid in water. Linear calibration curves were obtained in the range of 25–8000 ng/mL. The specificity, recovery, matrix effect, and stability also met the acceptance criteria of FDA guidance. The method was successfully applied to analyze plasma in acute myeloid leukemia (AML) patients. The peak plasma concentration (Cmax) of venetoclax in Chinese AML patient was 2966.0 ± 1595.0 ng/mL while the trough concentration (Cmin) was 1018.0 ± 729.4 ng/mL. Additionally, Cmax and Cmin showed a positive correlation with AST levels. Furthermore, Cmax was significantly higher in the older patients. The present method can be applied for TDM of venetoclax in treatment of hematological cancers.


  • Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease

    by Xin Li, Mengli Yu, Zhuo Zhu, Chao Lu, Meng Jin, Yuefeng Rao, Qingwei Zhao, Xiaoyang Lu, Chaohui Yu